Biologics for cardiovascular diseases: from bench to bedside

Area of Science:

• Cardiovascular Medicine
• Biotherapeutics
• Regenerative Medicine

Background:

• Cardiovascular diseases (CVDs) are a leading cause of mortality globally.
• Traditional therapies inadequately manage CVDs, necessitating novel approaches.
• Biologics offer a paradigm shift towards disease modification for CVD.

Purpose of the Study:

• To provide a comprehensive analysis of biologics in cardiovascular medicine.
• To focus on five key biological processes: cardiac regeneration, reverse remodeling, genetic cardiomyopathy correction, vascular function, and lipid metabolism.
• To highlight advancements and the transformative potential of biologics for CVD.

Main Methods:

• Review of current literature on biologics in cardiovascular medicine.
• Analysis of therapies targeting cardiac regeneration (stem cells, reprogramming, proliferation).
• Examination of approaches for reverse remodeling, genetic cardiomyopathies, vascular function, and lipid metabolism.

Main Results:

• Biologics show promise in cardiac regeneration and reverse remodeling.
• Gene therapies are advancing for genetic cardiomyopathies.
• Novel vascular function and lipid modulation therapies are emerging.
• Targeting PCSK9 and atherogenic lipoproteins redefines dyslipidemia management.

Conclusions:

• Biologics represent a transformative potential for targeted, personalized, and disease-modifying CVD treatments.
• These therapies address both pathophysiological roots and clinical manifestations of CVDs.
• Biologics are a promising frontier in cardiovascular medicine.